COVID-19 long haulers are having to deal with persistent migraines
Learn how gammaCore (nVNS) is being used by patients in the UK with Cluster Headache
electroCore Announces 510(k) Clearance of gammaCoreTM Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine
Emergency Use Authorization (EUA)
gammaCore SapphireTM CV (nVNS) receives EUA to treat patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow.
The science of
nVNS
nVNS therapy stimulates the vagus nerve, which has been proven to help people suffering from a variety of disorders.
Pioneers of technology. Innovators of medicine.
We are pioneering the use of nVNS to deliver bioelectronic medicine for patient benefit.
Our Product. Our Passion.
gammaCore™ (non-invasive vagus nerve stimulator) has become a solution for many people.
For payers
Take a few minutes to read 5 articles in support of coverage for gammaCore. We are committed to ensuring that appropriate patients have uninterrupted access to gammaCore.
electroCore is committed to the safety and care of our patients, providers, and employees during the COVID-19 pandemic. We have implemented several operational enhancements, research initiatives, and virtual capabilities to ensure patients who depend on us have uninterrupted access to gammaCoreTM (non-invasive vagus nerve stimulator). To learn more about our efforts please call (888) 903-CORE.
By clicking “Accept” you are agreeing to eletroCore to place cookies on your browser to gather web statistics that help us improve our site experience. Please read our Privacy Policy for more information on the types of cookies we use.
